SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-252467
Filing Date
2023-10-06
Accepted
2023-10-06 17:30:59
Documents
13
Period of Report
2023-10-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d509754d8k.htm   iXBRL 8-K 37156
2 EX-99.1 d509754dex991.htm EX-99.1 16952
  Complete submission text file 0001193125-23-252467.txt   187317

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tals-20231006.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20231006_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20231006_pre.xml EX-101.PRE 11255
7 EXTRACTED XBRL INSTANCE DOCUMENT d509754d8k_htm.xml XML 3336
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 231315012
SIC: 2836 Biological Products, (No Diagnostic Substances)